Variation in parathyroid hormone immunoassay results - A critical governance issue in the management of chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 26, Issue 11, 2011, Pages 3440-3445

  Sturgeon, Catharine M ^a   Sprague, Stuart M ^b   Metcalfe, Wendy ^c  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF CHICAGO   (United States)

^c Cirrus House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE;

ACCURACY; ANTIBODY SPECIFICITY; ARTICLE; CALIBRATION; CHRONIC KIDNEY DISEASE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; IMMUNOASSAY; MASS SPECTROMETRY; PARATHYROID HORMONE BLOOD LEVEL; PATIENT SAFETY; PRIORITY JOURNAL;

HUMANS; IMMUNOASSAY; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE;

EID: 80155171806     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr614     Document Type: Article

References (38)

1. Besser GM, Thorner MO. Comprehensive Clinical Endocrinology. 3rd edn. Mosby, 2002
2. Fraser WD. Hyperparathyroidism. Lancet 2009; 374: 145-158
3. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
4. Torres PU. The need for reliable serum parathyroid hormone measurements. Kidney Int 2006; 70: 240-243
5. Sprague SM. Renal bone disease. Curr Opin Endocrinol Diabetes Obes 2010; 17: 535-539
6. National Institute for Health and Clinical Excellence. NICE Technology Appraisal Guidance 117. Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Patients with End-Stage Renal Disease on Maintenance Dialysis Therapy. 2007. http://guidance.nice.org.uk/ nicemedia/live/11608/33857/ 33857.pdf (10 January 2011, date last accessed)
7. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38
8. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; S1-S130
9. Steddon S, Sharples E. Renal Association Clinical Practice Guideline: CKD-Mineral and Bone Disorders (CKD-MBD). 2011. http:// www.renal.org/clinical/ GuidelinesSection/CKD-MBD.aspx (10 September 2011, date last accessed)
10. Souberbielle J-C, Cavalier E, Jean G. Interpretation of serum parathyroid hormone concentrations in dialysis patients: What do the KDIGO guidelines change for the clinical laboratory? Clin Chem Lab Med 2010; 48: 769-774
11. Eastell R, Arnold A, Brandi ML et al. Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab 2009; 94: 340-350
12. Sturgeon CM, Seth J. Why do immunoassays for tumour markers give differing results?-A view from the UK National External Quality Assessment Schemes. Eur J Clin Chem Clin Biochem 1996; 34: 755-759
13. Stokes FJ, Ivanov P, Bailey LMet al. The effects of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism. Clin Chem 2011; 57: 138-140
14. Joly D, Drueke TB, Alberti C et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: A cross-sectional study. Am J Kidney Dis 2008; 51: 987-995
15. Cole DE, Webb S, Chan PC. Update on parathyroid hormone: New tests and new challenges for external quality assessment. Clin Biochem 2007; 40: 585-590
16. Herberth J, Monier-Faugere MC, Mawad HW et al. The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients. Clin Nephrol 2009; 72: 5-14
17. Nussbaum SR, Zahradnik RJ, Lavigne JR et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33: 1364-1367
18. Gao P, Scheibel S, D'Amour P et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: Implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001; 16: 605-614
19. TaniguchiM, Tanaka M, Hamano T et al. Comparison between whole and intact parathyroid hormone assays. Ther Apher Dial 2011; 15 (Suppl 1): 42-49
20. D'Amour P, Brossard J-H, Rakel A et al. Evidence that the aminoterminal composition of non-(1-84) parathyroid hormone fragments Starts before position 19. Clin Chem 2005; 51: 169-176
21. AFSSAPS. Report of Control of the Market on Medical Devices for In Vitro Measurement of Parathyroid Hormone (PTH). 2009. http://www. afssaps.fr/ Activites/Surveillance-du-marche-des-dispositifs-medicauxet- dispositifs-medicaux-de-diagnostic-in-vitro-DM-DMDIV/Dispositifsmedicaux- de-diagnostic-in-vitro-Operations-d-evaluations-et-de-controledu- marche/Dispositifs-medicaux-de-diagnostic-in-vitro-Operationsd- evaluations-et-de-controle-du-marche/Dosage-de-parathormone- PTH (10 September 2011, last date accessed)
22. Souberbielle JC, Boutten A, Carlier MC et al. Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 2006; 70: 345-350
23. Sturgeon CM, Ellis AR, Al-Sadie R. UK NEQAS for Peptide Hormones: Annual Review for 2009. Edinburgh, UK: UK NEQAS; 2010:26-30
24. Miller WG, Myers GL, Rej R. Why commutability matters. Clin Chem 2006; 52: 553-554
25. Burns C,Moore M, Sturgeon C et al.WHO International Collaborative Study of the proposed 1st International Standard for Parathyroid Hormone 1-84, human, recombinant. 2009. http://whqlibdoc.who.int/hq/ 2009/WHO-BS-09.2115-eng.pdf (10 September 2011, last date accessed)
26. Cantor T, Yang Z, Caraiani N et al. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: Implication for treatment decisions. Clin Chem 2006; 52: 1771-1776
27. Ates F, Koken T, Demir S et al. Comparison of three different immunoassay methods for the evaluation of intact parathyroid hormone levels in hemodialysis patients. Scand J Clin Lab Invest 2011; 71: 227-231
28. Almond A, Ellis A, Walker SW. Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease. Ann Clin Biochem 2011; (In press)
29. Kakuta T, Kato H, Komaba H et al. Parathyroid hormone control survey to determine inter-method and inter-lab variations in Japan. Ther Apher Dial 2011; 15 (Suppl 1): 50-55
30. Renal Registry. Chapter 10. Biochemistry Profile of Patients Receiving Dialysis in the UK in 2008: National and Centre-Specific Analyses. 2009. http://renalreg.com/Report-Area/Report%202009/Chap10-Renal09-web. pdf (10 September 2011, last date accessed)
31. Scottish Renal Registry Report 2009. Chapter SP2. Bone Mineral Metabolism. NHS National Services Scotland/Crown Copyright 2010 http://www.isdscotlandarchive.scot.nhs.uk/isd/6486.html (10 September 2011, last date accessed)
32. Pathology Harmony, 2011 http://www.pathologyharmony.co.uk/ NLCM%20 units.pdf (10 September 2011, last date accessed)
33. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (4 Suppl 3): S1-S201
34. Jackson DH, Banks RE. Banking of clinical samples for proteomic biomarker studies: A consideration of logistical issues with a focus on pre-analytical variation. Proteomics Clin Appl 2010; 4: 250-270
35. Nakai K, Komaba H, Fukagawa M. New insights into the role of fibroblast growth factor 23 in chronic kidney disease. J Nephrol 2010; 23: 619-625
36. Miller WG,Myers GL, Gantzer ML et al. Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem 2011; 57: 1108-1117
37. Kumar V, Barnidge DR, Chen L-S et al. Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. Clin Chem 2010; 56: 306-313
38. Lopez MF, Rezai T, Sarracino DA et al. Selected reaction monitoringmass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem 2010; 56: 281-290